Lucid Diagnostics (LUCD) Competitors

Talis Biomedical (NASDAQ:TLIS) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Which has higher earnings and valuation, TLIS or LUCD?

Lucid Diagnostics has higher revenue and earnings than Talis Biomedical. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talis Biomedical	$348K	43.61	-$62.01M	-$31.43	-0.27
Lucid Diagnostics	$2.98M	15.11	-$52.67M	-$1.27	-0.68

Do analysts rate TLIS or LUCD?

Talis Biomedical presently has a consensus target price of $5.00, indicating a potential downside of 39.98%. Lucid Diagnostics has a consensus target price of $4.33, indicating a potential upside of 403.88%. Given Talis Biomedical's stronger consensus rating and higher probable upside, analysts clearly believe Lucid Diagnostics is more favorable than Talis Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talis Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lucid Diagnostics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to TLIS or LUCD?

In the previous week, Talis Biomedical had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Talis Biomedical and 2 mentions for Lucid Diagnostics. Talis Biomedical's average media sentiment score of 0.93 beat Lucid Diagnostics' score of 0.64 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talis Biomedical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, TLIS or LUCD?

Talis Biomedical has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.

Does the MarketBeat Community favor TLIS or LUCD?

Lucid Diagnostics received 19 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 62.22% of users gave Lucid Diagnostics an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.

Company	Underperform	Outperform
Talis Biomedical	Outperform Votes 9 37.50%	Underperform Votes 15 62.50%
Lucid Diagnostics	Outperform Votes 28 62.22%	Underperform Votes 17 37.78%

Is TLIS or LUCD more profitable?

Lucid Diagnostics has a net margin of -1,576.60% compared to Lucid Diagnostics' net margin of -5,784.73%. Talis Biomedical's return on equity of 0.00% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talis Biomedical	-5,784.73%	-75.40%	-56.16%
Lucid Diagnostics	-1,576.60%	N/A	-106.33%

Do institutionals & insiders have more ownership in TLIS or LUCD?

43.8% of Talis Biomedical shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 46.0% of Talis Biomedical shares are owned by company insiders. Comparatively, 8.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Lucid Diagnostics beats Talis Biomedical on 12 of the 18 factors compared between the two stocks.